SynthesisHuman vaccines & immunotherapeutics2026
Serious adverse events following human papillomavirus vaccination: A systematic review and meta-analysis of post-marketing evidence.
Synthesis in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Real-world safety data of human papillomavirus vaccines after marketing in Shandong, China, August 2017-October 2025.Human vaccines & immunotherapeutics · 2026Article
- Knowledge and attitudes of medical students about human papillomavirus (HPV) and HPV vaccine: A cross-sectional survey in Inner Mongolia, China.Human vaccines & immunotherapeutics · 2026Article
- The Cancer That Could Disappear.Clinical journal of oncology nursing · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomavirus (HPV) vaccines are a critical tool in cancer prevention, yet concerns about serious adverse events (SAEs) have fueled public hesitancy and constrained vaccination uptake. This systematic review aimed to determine the proportion of adverse events that were SAEs, rate of SAEs following HPV vaccination and their association from post-marketing observational studies. We conducted a search in PubMed, EMBASE, and Web of Science databases in March 2025. Studies published in English reporting SAEs after HPV vaccination from post-licensure studies or surveillance were included. Of the 258 identified records, 24 articles were included in the systematic review: 15 in the meta-analysis and 9 in the narrative synthesis. Among the studies included in the meta-analysis, four found no SAEs; the pooled proportion of adverse events that were SAEs was 3.67% (95% confidence interval, CI: 1.19%, 7.30%), I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.